Presently there is no specific provision under Drugs and Cosmetics Rules for payment of compensation in case of clinical trial related injury or death of the subject. However, the Good Clinical Practice (GCP) Guidelines for Clinical Trials of India under para 2.4.7 provides that the research subject who suffers physical injury as a result of their participation in clinical trials are entitled to financial or other assistance to compensate them equitably for any temporary or permanent impairment or disability subject to confirmation from Ethics Committee.
In case of death, their dependents are entitled to material compensation. Guidelines further provide that it is the obligation of the sponsor to pay the compensation. The concerns were also raised in the Parliament and other forums regarding payment of compensation in the cases of injury or death in clinical trial. This guidance document describes the methods to be followed by the Ethics Committees for calculating the quantum of financial compensation to be paid in case of clinical trial related injury or death.
For further details visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf
The Categorisation Problem Of all the challenges in India’s Cosmetic Import registration process, product categorisation is one of the most underestimated. Under the Cosmetics Rules, 2020, CDSCO..
For foreign Medical Device companies entering India, the authorized agent is not just a compliance checkpoint — it is a strategic regulatory role. The right appointment can support licensing procedu..
Why India Demands a Dedicated Biosimilar Strategy India is one of the fastest-growing Biosimilar markets in the world, driven by a large patient population, expanding government healthcare coverage un..
India
Global
Sales: +91 7672005050
Reception: +91-11-45214546
9 am to 6 pm (Monday to Friday)